1. DrGeoffreyMartinBoxer
Date of Birth 27th
August 1956 (London) - United Kingdom Resident
Status Married to Linda, with one son James (aged 31 years).
Most Recent
Employment
Grants
Previous
Employment
Principal Research Associate 2010-2015 (Department of Oncology) – Retired (2015)
Personal Research Area: Identification of factors influencing uptake/distribution of
antibody/fusion protein molecules in colorectal cancer models systems and patients.
UCL Cancer Institute, 72 Huntley Street, London WC1E 6BT
HEAD OF DEPARTMENT: Professor Richard Begent (2000 -2010), Professor Hilary
Calvert (2010-15), Professor Daniel Hochhauser (2016-)
Co-Investigator of an MRC DPFS grant (2011-2014) G1001497: Development of a
novel therapy, combining radioimmunotherapy with conventional therapy, for the
improved treatment of advanced colorectal cancer. Funding awarded £811,000
Laboratory Manager (Biomedical Scientist GRADE 4 ***) 1990-2010, University of
London Teacher (UCL) since 1992- and LTN Business Fellow 2003-10
Targeting & Imaging Group (Oncology) - UCL Cancer Institute, UCLH Medical School,
UCL (London), 72 Huntley Street. HEAD OF DEPARTMENT: Professor Richard Begent
Responsibilities – TECHNICAL & ADMINISTRATIVE
1) Organisation, operation of day to day running, administration of departmental affairs
and responsibility for 50 employees
2) Business Administration
• Liaising with UCL Business
• Helping to set up contracts
• Negotiating deals for UCL with commercial, government charitable sectors
• Project managing business ventures
• Developing strategic alliances within the healthcare space
• Raising funding through applications, proposals and submissions
• Critically appraising proposals and performing due diligence
• Administration of translational funding streams
• Preparing costing for funders
2) Departmental Health & Safety Supervisor for Department of Oncology (Royal Free and
Bloomsbury campuses of UCL).
3) Organisation of departmental ordering and accounting procedures.
4) Financial control of departmental budget (£10 M plus)
Responsibilities – SCIENTIFIC & RESEARCH
1) Head of the Departmental cellular pathology unit.
2) Interaction with other department unit section leaders of: molecular biology; cellular
biology; protein chemistry; antibody/fusion protein production unit; physics unit; clinical
trials team; bioinformatics group
Project Leader Oncology and author of successful business case: for the Phase I/II
Cancer Clinical Trials Centre (originally planned for Royal Free Clinical campus of UCL)
sponsored by UCL-CIRT Cancer Institute Research Trust (£4.1M funding secured).
Project and part of funding recently transferred to implement, support and develop
Contact Details:
19 Queens Road, Finchley, London N3 2AG
Mobile: 07984467189
E-Mail: geoff.boxer@virginmedia.com

2. the Clinical Research Facility (CRF) at UCLH (Phase 2) as part of the UCLH
Comprehensive Biomedical centre (CBRC) and GCLP Lab at UCL Cancer Institute
Charing Cross & Westminster Hospital Medical School
Department of Histopathology (1980-1983)
Biomedical Scientific Officer GRADE 3: Head of Department: Professor K. Henry
EDUCATION 1972.1974 3 A-Levels: Biology, Chemistry, Geography:
1974.1976 HNC Biomedical Sciences - University of Westminster (London)
1976.1978 Degree in Histopathology and Cytology (Fellowship Exam) FIBMS - University
of Westminster (London)
2005-2008 PhD awarded on the ‘Basis of Published Works’ Staffordshire University
(Supervisor Dr Stephen Merry)
AWARDS Fellow of the Institute of Biomedical Sciences (1978- )
QUALIFICATIONS Member of the British Association of Cancer Research (1986- )
UK State Registered Scientist (1976- )
Member of the American Association of Cancer Research
HONORARY UCL Business Fellow and LTN Alumni Business Fellow 2003- (Consultant to the London
Technology Network). Training at London Business School (2003-4)
INVITED Workshop Leader for the ‘NHS Medical Innovations Forum’
SPEAKER (Harrogate 2008, London 2009)
SMi Conference on Cancer Clinical Trials (London, June 2007 & 2008)
European Clinical Trial Summit (ACT) (Amsterdam October 2007)
ADVISORY LTN Special Interest Group (SIG) – Advisory Board Member on Emerging Medical
Technologies (2010-)
TEACHING UCL University Teacher and Supervisor to: Intercalated BSc Students (UCL).
MSc Students (UCL). PhD Students (UCL), MD Thesis (UCL) Dr Ghazna Saddiqui
Lecturer to: BSc/MSc Students(UCL) UCLH Medical Students (Oncology Module)
SKILLS Cellular Pathology (including: tissue processing, microtomy, cryotomy, special stains
immunohistochemistry, autoradiography, radioluminography).
Molecular Biology techniques and experience: DNA extraction, PCR analysis, genomic,
mRNA, and DNA methylation studies (including loss of heterozygosity studies, SNP
analysis). Protein chemistry (column chromatography/ gel-electrophoreisis
Microscopy (including: transmission EM, bright-field, phase contrast and fluorescence).
Image Analysis (including: using Zeiss KS-300 system and digital imaging camera
AXIOCAM, Apotome, deconvolution of Z-stacks and 3D reconstruction). Biological
Models: Familiarity with animal models (xenograft and orthotopic models of cancer)
and handling of animal tissues. Design of experimentation
Clinical Trials: Experience of helping to design clinical trials through translational
approaches. Performing of clinical trials for cancer
Compliance: Experience of compliance (GCLP, GMP and IMP licences, SOP and quality
assurance). Management of GCLP areas for clinical trials as part of the UCL
Experimental Cancer Medicine Centre (ECMC)
Computer skills (including: familiarity with word processing packages - WORD and
WORDPERFECT; Spreadsheets (EXCEL; SPSS statistics package; ACCESS; Image
processing software – PHOTOSHOP; Interactive Data language IDL; Presentation
packages – POWERPOINT. Use of bioinformatics databases. Familiarity with and use of many
ORACLE databases (UCL) for human resource, costing and finance. Use of web-connected
databases searching of scientific data, and literature (Web of Science/Knowledge/ONIX/PubMed

3. DIRECTORSHIP Director on the Board of Sports Club Ltd (UCSOG affiliated company) 2015 -
PUBLICATIONS: 1980-2015 (Selected from 85 in total)
 Vassileva V, Rajkumar VS, Mazzantini M, Robson M, Badar A, Sharma S, Aarstad E, Hochhauser D, Lythgoe M,
Boxer G, Pedley R. Significant Therapeutic Efficacy with Combined Radioimmunotherapy and in Pre-clinical
Models of Colorectal Cancer. J Nucl Med, 2015, 56, 1239-1245.
 Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR
inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct
models of colon adenocarcinoma. Tumour Biol. 33, 2019-2029, 2012
 Siddiqui GK, Maclean AB, Elmasry K, Wong Te Fong A, Morris RW, Rashid M, Begent RH, Boxer GM.
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients
with epithelial ovarian cancer. Angiogenesis, 2011, 14 : 2 : 155-161
 Dearling J, Flynn A, Qureshi U, Whiting S, Boxer G, Begent R, Pedley RB. Localization of radio-labeled anti-CEA
antibody in subcutaneous and intrahepatic colorectal xenografts: Influence of tumor size and location within
host organ on antibody uptake. Nucl Med Biol 36: 883-894, 2009.
 Fidarova, EF, El-Emir, E, Boxer G, Qureshi, U, Dearling, JLJ, Robson, MP, Trott, KR, Pedley, RB.
Microdistribution of targeted, fluorescently- labeled anti-carcinoembryonic antigen antibody in metastatic
colorectal cancer: implications for radioimmunotherapy. 2008, 14, 9, 2639-2646.
 El-Emir, E, Qureshi, U, Dearling JLJ, Boxer, GM, Clatworthy, I, Folarin, AA, Robson, MP, Nagl, S, Konerding,
MA, Pedley, RB. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal
carcinomas. Cancer Res., 67, 24, 11896-11905, 2007.
 El-Emir E, Boxer G.M., Petrie, I., Boden, R.W., Dearling, J., Begent R.H.J. and Pedley, R.B. Tumour parameters
affected by combretatastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice.
Eur. J. Cancer, 41, 799-806, 2005.
 Boxer, G.M., Tsiompanou, E., Levine, T., Watson, R. and Begent, R.H.J. Immunohistochemical Expression of
Vascular Endothelial Growth Factor and Microvessel Counting as Prognostic Indicators in Node-Negative
Colorectal Cancer. Tumor Biol. 26: 1-8, 2005
 Dearling, J.L.J., Flynn, A.A., Sutcliffe-Goulden, J., Petrie, I. A., Boden, R., Green, A.J, Boxer, G.M., Begent, R.H.J.
and Pedley, R.B. Analysis of the Regional Uptake of Radiolabeled Deoxyglucose Analogs in Human Tumor
Xenografts. J Nucl Med, 45:101–107, 2004.
 Pedley, R.B., El-Emir, E., Flynn A.A., Boxer, G.M., Dearling, J.L.J., Raleigh, J.A., Hill, S.A., Stuart, S., Motha, R.,
and Begent, R.H.J. Synergy between vascular targeting agents and antibody-directed therapy. Int. J.
Radiation Oncology Biol. Phys., 54, No 5 1524-1531, 2002.
 Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Bhatia J, Morris, R. and Begent RHJ. Antibody and
radionuclide characteristics and the enhancement of effectiveness of radioiummunotherapy by selective
dose delivery to radiosensitive areas of tumour. Int. J. Radiat. Biol 78 (5): 407-415 2002.
 Flynn AA, Green AJ, Pedley RB Boxer GM, Boden R and Begent RHJ A mouse model for calculating the absorbed
beta-particle dose from I-131- and Y-90-labeled immunoconjugates, including a method for dealing with
heterogeneity in kidney and tumor. Radiat. Res. 156 (1): 28-35 Jul 2001(A).
 Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ. and Begent RHJ.
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-
phosphate. Cancer Res. 61 (12): 4716-4722 Jun 15 2001.
 Cooke SP, Boxer GM, Lawrence LPedley RB, Spencer DIR, Begent RHJ. and Chester KA A strategy for
antitumor vascular therapy by targeting the vascular endothelial growth factor : receptor complex. Cancer
Res. 61 (9): 3653-3659 May 1 2001
 Flynn AA, Boxer GM, Begent RHJ and Pedley RB. Relationship between tumour morphology, antigen and antibody
distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol. Immunother. 50 (2):
77-81 Apr 2001 (B).
 Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AAM,
Winslet MC, Dhillon AP, Hilson, AJW and Begent RHJ Radioimmunoguided surgery in colorectal cancer
using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 6 (5) 1711-1719 2000.
 Boxer, G.M., Stuart-Smith, S., Flynn, A. A., Green, A.J. & Begent, R.H.J. Radioimmunolumigraphy: a tool for
relating tissue antigen concentration to clinical outcome. Br. J. Cancer, 80: 922-926, 1999.
 Boxer, G.M., Begent, R.H.J., Kelly, A.M.B., Southall, P.J., Blair, S.B., Theodorou, N.A., Dawson, P.M. and
Lederman, J.A. Factors influencing variability of localization of antibodies to CEA in patients with colorectal
carcinoma – implications for radioimmunotherapy. Br.J.Cancer, 65: 825-831, 1992.

4.  Boxer, G.M., Abassi, A, Pedley, R.B.& Begent, R. Localization of monoclonal antibodies reacting with different
epitopes on carcinoembryonic antigen implications for targeted therapy. Br. J. Cancer, 69: 307-314, 1994.
 Chester, K.A., Begent, R.H.J., Robson, L., Keep, P.A., Pedley, R.B., Boden, J.A., Boxer, G.M., Green, A.J.,
Winter, G., Cochet, O. & Hawkins, R.E. Phage libraries for generation of clinically useful antibodies. Lancet,
343: 455-456, 1994.